Home/Filings/4/0001493152-23-012789
4//SEC Filing

Backenroth Samuel 4

Accession 0001493152-23-012789

CIK 0001603207other

Filed

Apr 17, 8:00 PM ET

Accepted

Apr 18, 4:36 PM ET

Size

7.1 KB

Accession

0001493152-23-012789

Insider Transaction Report

Form 4
Period: 2023-03-31
Backenroth Samuel
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Restricted Stock Units

    2023-03-31525,000175,000 total
    Ordinary Shares (525,000 underlying)
  • Exercise/Conversion

    Ordinary Shares

    2023-03-31+525,000525,000 total
Footnotes (2)
  • [F1]Represents the vesting and settlement of a portion of restricted stock units ("RSUs") previously granted to the Reporting Person. Each RSU represents a contingent right to receive one Ordinary Share, par value NIS 0.01, with an exercise price of NIS 0.01 per Ordinary Share.
  • [F2]75% of the RSUs vested on March 31, 2023, with the remaining 25% vesting on August 9, 2024. The RSUs have no expiration date and have an exercise price of NIS 0.01 per Ordinary Share.

Documents

1 file

Issuer

Vascular Biogenics Ltd.

CIK 0001603207

Entity typeother

Related Parties

1
  • filerCIK 0001579887

Filing Metadata

Form type
4
Filed
Apr 17, 8:00 PM ET
Accepted
Apr 18, 4:36 PM ET
Size
7.1 KB